Compare Merck & Co., Inc. (MRK) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Wipro Limited — how do they compare? Merck & Co., Inc. trades at $130.41 (market cap $323.00B), while Wipro Limited trades at $1.98 (market cap $19.22B). The key difference: Merck & Co., Inc. is far larger — about 16.8× Wipro Limited's market cap, and Wipro Limited pays the higher dividend (4.35%). Which is the better fit depends on your goals.
| MRK | WIT | |
|---|---|---|
Market Cap | $323.00B | $19.22B |
Sector | Health | Technology |
52-Week High | $131.84 | $3.06 |
52-Week Low | $77.60 | $1.78 |
Enterprise Value | $369.77B | $17.30B |
Dividend Yield | 2.6% | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $130.45, up 1.46% on the day, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, though the P/E ratio of 104.74 reflects high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives.
The outlook for MRK is positive, supported by analyst consensus with a $139.90 price target and 67.57% buy ratings. Key opportunities include pipeline expansion via M&A and solid cash flow generation, while risks involve elevated debt levels and competitive pressures in the pharma sector. Earnings beats in recent quarters underscore operational strength, but investors should monitor integration execution from acquisitions.
WIT trades at $2.02, up 1.51% today, with a neutral technical signal and bearish moving average trend. The company reported a net income margin of 13.92% and ROE of 16.09% for 2025, with revenue of $890.88 billion. Recent earnings have missed expectations, but partnerships with Databricks and ServiceNow aim to drive AI-led growth. Cash flow from operations remains strong at $169.43 billion, supporting a $0.02 dividend.
The outlook is mixed: valuation ratios like P/E of 15.25 and EV/EBITDA of 7.83 appear reasonable, but earnings misses and competitive pressures pose risks. Analyst sentiment is cautious with only 19% buy ratings. Key opportunities include AI expansion, while risks involve client spending cuts and margin pressure from wage increases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
